Peptide-based blood coagulant - Haemostatix

Drug Profile

Peptide-based blood coagulant - Haemostatix

Alternative Names: Haemostasis therapeutic - Haemostatix; Haemostat topical - Haemostatix; PeproStat; PeproStat Liquid; Peptide-based antihaemorrhagic - Haemostatix

Latest Information Update: 25 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Haemostatix
  • Class
  • Mechanism of Action Fibrinogen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Surgical blood loss

Most Recent Events

  • 18 Apr 2017 Phase-II clinical trials in Surgical blood loss (Prevention) in Poland (Topical) (EudraCT2016-003661-26)
  • 01 Jul 2014 Phase-I clinical trials in Surgical blood loss (Prevention) in United Kingdom (Topical, liquid)
  • 01 Jan 2014 Preclinical trials in Surgical blood loss (Prevention) in United Kingdom (Topical, paste)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top